Login / Signup
Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance.
Takehiro Nakao
Kenichi Harano
Masashi Wakabayashi
Yoichi Naito
Hiroshi Tanabe
Toru Mukohara
Published in:
Gynecologic oncology reports (2024)
Platinum-based chemotherapy rechallenge is reasonable for patients with platinum-sensitive disease, using the traditional PFI cutoff of 6 months, even when the PFI is obtained with a maintenance PARP inhibitor.
Keyphrases
</>
dna damage
dna repair
locally advanced
squamous cell carcinoma
radiation therapy